Log in

Relevant bibliographies by topics / Novel therapeutic drugs / Journal articles

To see the other types of publications on this topic, follow the link: Novel therapeutic drugs.

Journal articles on the topic 'Novel therapeutic drugs'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Novel therapeutic drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hashimoto, Kenji. "Editorial:[Novel Therapeutic Drugs for Neuropsychiatric Disorders]." Open Medicinal Chemistry Journal 4, no. 2 (2010): 1–2. http://dx.doi.org/10.2174/1874104501004020001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kehler, Jan, and Jacob Nielsen. "PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia." Current Pharmaceutical Design 17, no. 2 (2011): 137–50. http://dx.doi.org/10.2174/138161211795049624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hirschfield, G. M., M. D. Smith, S. V. Ley, et al. "Therapeutic Inhibition of C-Reactive Protein-Novel Drugs, Novel Mechanisms." Clinical Science 104, s49 (2003): 65P—66P. http://dx.doi.org/10.1042/cs104065pb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kerwin, R., and M. Owen. "Genetics of novel therapeutic targets in schizophrenia." British Journal of Psychiatry 174, S38 (1999): 1–4. http://dx.doi.org/10.1192/s000712500029805x.

Full text

Abstract:

For many years, following the introduction of chlorpromazine in the 1950s, little progress was made in the discovery of new drugs for schizophrenia (Reynolds, 1992). Dopamine D2 receptor blockade was recognised as the only therapeutic target for antipsychotics (Creese et al, 1976) and the inevitable consequences of striatal blockade remained problematic. However, the strategies and stimuli for discovery of new drugs changed with the introduction of new, atypical antipsychotics in the 1990s. These include clozapine, remoxipride (now withdrawn), olanzapine, risperidone and sertindole (Kerwin &am

APA, Harvard, Vancouver, ISO, and other styles

5

Muralidharan, V., and M. Deecaraman. "A Source of Novel Therapeutic Drugs-Marine Actinomycetes." Research Journal of Pharmacy and Technology 10, no. 10 (2017): 3598. http://dx.doi.org/10.5958/0974-360x.2017.00652.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gasparini, Giampietro. "Antiangiogenic drugs as a novel anticancer therapeutic strategy." Critical Reviews in Oncology/Hematology 26, no. 3 (1997): 147–62. http://dx.doi.org/10.1016/s1040-8428(97)10001-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Szallasi, Arpad, Francisco Cruz, and Pierangelo Geppetti. "TRPV1: a therapeutic target for novel analgesic drugs?" Trends in Molecular Medicine 12, no. 11 (2006): 545–54. http://dx.doi.org/10.1016/j.molmed.2006.09.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Yu, LX, W. Jiang, X. Zhang, et al. "Novel bioequivalence approach for narrow therapeutic index drugs." Clinical Pharmacology & Therapeutics 97, no. 3 (2014): 286–91. http://dx.doi.org/10.1002/cpt.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Verma, Ujala, R. Sharma, P. Gupta, B. Kapoor, G. Bano, and V. Sawhney. "New uses for old drugs: Novel therapeutic options." Indian Journal of Pharmacology 37, no. 5 (2005): 279. http://dx.doi.org/10.4103/0253-7613.16850.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cunha, Rita F., Sandra Simões, Manuela Carvalheiro, José M. Azevedo Pereira, Quirina Costa, and Andreia Ascenso. "Novel Antiretroviral Therapeutic Strategies for HIV." Molecules 26, no. 17 (2021): 5305. http://dx.doi.org/10.3390/molecules26175305.

Full text

Abstract:

When the first cases of HIV infection appeared in the 1980s, AIDS was a deadly disease without any therapeutic alternatives. Currently, there is still no cure for most cases mainly due to the multiple tissues that act as a reservoir for this virus besides the high viral mutagenesis that leads to an antiretroviral drug resistance. Throughout the years, multiple drugs with specific mechanisms of action on distinct targets have been approved. In this review, the most recent phase III clinical studies and other research therapies as advanced antiretroviral nanodelivery systems will be here discuss

APA, Harvard, Vancouver, ISO, and other styles

11

Stein, Eytan M., and Martin S. Tallman. "Emerging therapeutic drugs for AML." Blood 127, no. 1 (2016): 71–78. http://dx.doi.org/10.1182/blood-2015-07-604538.

Full text

Abstract:

Abstract Multiple new drugs are being developed to treat acute myeloid leukemia (AML), including novel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific mutant enzymes. Next-generation sequencing has allowed us to discover the genetic mutations that lead to the development and clinical progression of AML. Studies of clonal hierarchy suggest which mutations occur early and dominate. This has led to targeted therapy against mutant driver proteins as well as the development of drugs such as CPX-351 and SGN-CD33A whose mechanisms of action and effica

APA, Harvard, Vancouver, ISO, and other styles

12

Jadidi-Niaragh, Farhad, and Abbas Mirshafiey. "Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs." Recent Patents on Inflammation & Allergy Drug Discovery 5, no. 1 (2011): 66–80. http://dx.doi.org/10.2174/187221311794474900.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mathew, Sanjay J., Husseini K. Manji, and Dennis S. Charney. "Novel Drugs and Therapeutic Targets for Severe Mood Disorders." Neuropsychopharmacology 33, no. 9 (2008): 2080–92. http://dx.doi.org/10.1038/sj.npp.1301652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Zalcberg, J. R. "Monoclonal antibodies to drugs: Novel diagnostic and therapeutic reagents." Pharmacology & Therapeutics 28, no. 3 (1985): 273–85. http://dx.doi.org/10.1016/0163-7258(85)90055-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Hong, Min Hee. "Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents." Kidney Research and Clinical Practice 40, no. 3 (2021): 344–54. http://dx.doi.org/10.23876/j.krcp.21.037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Yatoo, Mohd Iqbal, Oveas Raffiq Parray, Riyaz Ahmed Bhat, et al. "Emerging Antibiotic Resistance in Mycoplasma Microorganisms, Designing Effective and Novel Drugs / Therapeutic Targets: Current Knowledge and Futuristic Prospects." Journal of Pure and Applied Microbiology 13, no. 1 (2019): 27–44. http://dx.doi.org/10.22207/jpam.13.1.03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Aditya, Suruchi, Suryakant Mathur, and Aditya Rattan. "Dapagliflozin: A Novel Therapeutic Approach to Treat Diabetes." JMS SKIMS 14, no. 2 (2011): 43–45. http://dx.doi.org/10.33883/jms.v14i2.81.

Full text

Abstract:

Current approaches to treatment of diabetes have many drawbacks. Most of the oral hypoglycemic drugs target the insulin secretion and action. Sodium Glucose co transporters (SGLT)-2 inhibitors are a recent addition to antihyperglycemic drugs that act by reducing glucose reabsorption from the renal filtrate so that bulk of glucose is excreted in the urine. Dapagliflozin, the first in this new class of drugs, is a SGLT2 inhibitor. It causes loss in body weight and is not associated with major hypoglycemic events.Dapagliflozin is currently in advanced development for use alone or in combination w

APA, Harvard, Vancouver, ISO, and other styles

18

Chawla, Pooja, and Monika Mis. "Polymeric Drugs: A Novel Approach to Drug Delivery System." International Journal of Pharmaceutical Sciences and Nanotechnology 6, no. 1 (2013): 1925–34. http://dx.doi.org/10.37285/ijpsn.2013.6.1.2.

Full text

Abstract:

 This review article describes the current status and recent advances of polymeric drugs with regard to their application in drug delivery system. Essentially polymer-drug conjugation aims to achieve improved drug targeting, decrease drug toxicity and overcome mechanisms of drug resistance. First generation conjugates used linear monomethoxy PEGs and other linear polymers. Modern polymeric chemistry is increasingly producing new polymeric architectures such as dendrimers, hyper branched polymers and hybrid macromolecular structures (such as star polymers, linear graft and dendronized lin

APA, Harvard, Vancouver, ISO, and other styles

19

Tardiolo, Giuseppe, Placido Bramanti, and Emanuela Mazzon. "Migraine: Experimental Models and Novel Therapeutic Approaches." International Journal of Molecular Sciences 20, no. 12 (2019): 2932. http://dx.doi.org/10.3390/ijms20122932.

Full text

Abstract:

Migraine is a disorder affecting an increasing number of subjects. Currently, this disorder is not entirely understood, and limited therapeutic solutions are available. Migraine manifests as a debilitating headache associated with an altered sensory perception that may compromise the quality of life. Animal models have been developed using chemical, physical or genetic modifications, to evoke migraine-like hallmarks for the identification of novel molecules for the treatment of migraine. In this context, experimental models based on the use of chemicals as nitroglycerin or inflammatory soup we

APA, Harvard, Vancouver, ISO, and other styles

20

Tyagi, Sanjay, and Vishal Batra. "Novel Therapeutic Approaches of Pulmonary Arterial Hypertension." International Journal of Angiology 28, no. 02 (2019): 112–17. http://dx.doi.org/10.1055/s-0039-1692140.

Full text

Abstract:

AbstractPulmonary arterial hypertension (PAH) is an uncommon disease characterized progressive remodeling of pulmonary vasculature. Although treatment for PAH have improved in last two decades but the outcome remains fatal. Currently, the therapies for PAH target three well-established pathways the nitric oxide (NO) pathway, endothelin receptors, and prostanoids. There are multiple potential targets for development of newer drugs in PAH which requires meticulous research and clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

21

Hashimoto, Kenji. "Glycine Transporter-1 Inhibitors as Novel Therapeutic Drugs for Schizophrenia." Central Nervous System Agents in Medicinal Chemistry 7, no. 3 (2007): 177–82. http://dx.doi.org/10.2174/187152407781669161.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Miguel, J. San, M. V. Mateos, and E. Ocio. "77 New drugs and novel therapeutic principles in multiple myeloma." European Journal of Cancer Supplements 7, no. 2 (2009): 21. http://dx.doi.org/10.1016/s1359-6349(09)70074-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Mathew, Sanjay J., Husseini K. Manji, and Dennis S. Charney. "Erratum: Novel Drugs and Therapeutic Targets for Severe Mood Disorders." Neuropsychopharmacology 33, no. 9 (2008): 2300. http://dx.doi.org/10.1038/npp.2008.84.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sendrowski, Krzysztof, and Wojciech Sobaniec. "Antiepileptic drugs as a novel therapeutic strategy in Alzheimer's disease." Pharmacological Reports 67, no. 1 (2015): 169. http://dx.doi.org/10.1016/j.pharep.2014.11.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bencherif, Merouane, Terry A. Hauser, Kristen G. Jordan, and Gregory J. Gatto. "Therapeutic Potential of Novel Selective Drugs Targeting Nicotinic Acetylcholine Receptors." Journal of Molecular Neuroscience 30, no. 1-2 (2006): 17–18. http://dx.doi.org/10.1385/jmn:30:1:17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Korting, Hans C. "Tagung der DPHG:„Targets, Drugs and Carriers— Novel Therapeutic Approaches”." Pharmazie in unserer Zeit 33, no. 4 (2004): 328–29. http://dx.doi.org/10.1002/pauz.200490079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Iretiola Builders, Modupe, Joseph Oyepata Simeon, Timothy Olugbenga Ogundeko, and Philip Builders. "Antimalarial Drugs and COVID -19." Sumerianz Journal of Medical and Healthcare, no. 312 (December 15, 2020): 111–16. http://dx.doi.org/10.47752/sjmh.312.111.116.

Full text

Abstract:

The coronavirus disease 2019 (COVID-19) is a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that is ravaging the world. Therefore, the need to find new preventive and therapeutic drug at the earliest possible time additionally to the implementation of preventive measures such as early detection, isolation and treatment of cases as well as minimization of transmission through physical interaction. Moreover, specific vaccines and yet effective treatment that target the 2019. This review focuses on the use of antimalarial drugs as therapeutics interventions for

APA, Harvard, Vancouver, ISO, and other styles

28

Iretiola Builders, Modupe, Joseph Oyepata Simeon, Timothy Olugbenga Ogundeko, and Philip Builders. "Antimalarial Drugs and COVID -19." Sumerianz Journal of Medical and Healthcare, no. 312 (December 15, 2020): 111–16. http://dx.doi.org/10.47752/sjmh.312.111.116.

Full text

Abstract:

The coronavirus disease 2019 (COVID-19) is a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that is ravaging the world. Therefore, the need to find new preventive and therapeutic drug at the earliest possible time additionally to the implementation of preventive measures such as early detection, isolation and treatment of cases as well as minimization of transmission through physical interaction. Moreover, specific vaccines and yet effective treatment that target the 2019. This review focuses on the use of antimalarial drugs as therapeutics interventions for

APA, Harvard, Vancouver, ISO, and other styles

29

Stahl, Stephen M. "Multifunctional Drugs: A Novel Concept for Psychopharmacology." CNS Spectrums 14, no. 2 (2009): 71–73. http://dx.doi.org/10.1017/s1092852900000213.

Full text

Abstract:

Beginning this month and appearing periodically in future columns, “Trends in Psychopharmacology” will cover a new concept and hot topic in the field, namely, that of “multifunctional drugs.” The concept is presented in overview here. Future installments will cover specific drugs in greater depth. Multifunctional drugs include those agents with more than one putative therapeutic mechanism of action.

APA, Harvard, Vancouver, ISO, and other styles

30

Fialho, Arsenio M., Prabhakar Salunkhe, Sunil Manna, Sidharth Mahali, and Ananda M. Chakrabarty. "Glioblastoma Multiforme: Novel Therapeutic Approaches." ISRN Neurology 2012 (February 8, 2012): 1–10. http://dx.doi.org/10.5402/2012/642345.

Full text

Abstract:

The current therapy for glioblastoma multiforme involves total surgical resection followed by combination of radiation therapy and temozolomide. Unfortunately, the efficacy for such current therapy is limited, and newer approaches are sorely needed to treat this deadly disease. We have recently described the isolation of bacterial proteins and peptides with anticancer activity. In phase I human clinical trials, one such peptide, p28, derived from a bacterial protein azurin, showed partial and complete regression of tumors in several patients among 15 advanced-stage cancer patients with refract

APA, Harvard, Vancouver, ISO, and other styles

31

Dembic, Zlatko. "Antitumor Drugs and Their Targets." Molecules 25, no. 23 (2020): 5776. http://dx.doi.org/10.3390/molecules25235776.

Full text

Abstract:

Through novel methodologies, including both basic and clinical research, progress has been made in the therapy of solid cancer. Recent innovations in anticancer therapies, including immune checkpoint inhibitor biologics, therapeutic vaccines, small drugs, and CAR-T cell injections, mark a new epoch in cancer research, already known for faster (epi-)genomics, transcriptomics, and proteomics. As the long-sought after personalization of cancer therapies comes to fruition, the need to evaluate all current therapeutic possibilities and select the best for each patient is of paramount importance. Th

APA, Harvard, Vancouver, ISO, and other styles

32

Benfaremo, Devis, Valentino Paci, Michele Maria Luchetti, and Armando Gabrielli. "Novel Therapeutic Approaches and Treatment Targets for Psoriatic Arthritis." Current Pharmaceutical Biotechnology 22, no. 1 (2020): 85–98. http://dx.doi.org/10.2174/1389201021666200928095521.

Full text

Abstract:

Background: Psoriatic Arthritis (PsA) is the most common extracutaneous manifestation of psoriasis. This chronic inflammatory arthritis is burdened with significant morbidity, leading to irreversible joint damage and disability. In recent years, a deeper understating of its pathogenesis has led to the development of several new drugs targeting different pathways. Objectives: This review aims to highlight the clinical efficacy and safety of the novel agents that have become recently available for the treatment of PsA, as well as new promising therapeutic targets that are being evaluated in clin

APA, Harvard, Vancouver, ISO, and other styles

33

Sawyer, Abigail. "Developing drugs for the ‘undruggable’." BioTechniques 69, no. 4 (2020): 239–41. http://dx.doi.org/10.2144/btn-2020-0134.

Full text

Abstract:

There are up to 650,000 ‘undruggable’ protein-protein interactions (PPIs) in the human interactome that can be potentially considered as novel therapeutic targets. How does the ‘undruggable’ become ‘druggable’?

APA, Harvard, Vancouver, ISO, and other styles

34

Usha, A. Lakshmi, M. Kusama Kumari, E. Radha Rani, and M. Ramadevi. "A Novel Technique for Intradermal Delivery of Drugs – Coated Polymeric Needles." Asian Journal of Research in Pharmaceutical Sciences 11, no. 2 (2021): 133–39. http://dx.doi.org/10.52711/2231-5659.2021-11-2-7.

Full text

Abstract:

The barrier properties of the topmost layer of the skin, stratum corneum have significant limitations for successful systemic delivery of a wide range of therapeutic molecules, especially macromolecules and genetic material. One solution is to utilize microneedles (MNs), which are capable of painlessly traversing through the stratum corneum and directly translocating protein drugs into the systematic circulation. This strategy involves the use of micron sized needles fabricated from different materials and using different geometries to create transient aqueous conduits across the skin. Microne

APA, Harvard, Vancouver, ISO, and other styles

35

Amero, Paola, Soumen Khatua, Cristian Rodriguez-Aguayo, and Gabriel Lopez-Berestein. "Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology." Cancers 12, no. 10 (2020): 2889. http://dx.doi.org/10.3390/cancers12102889.

Full text

Abstract:

A relatively new paradigm in cancer therapeutics is the use of cancer cell–specific aptamers, both as therapeutic agents and for targeted delivery of anticancer drugs. After the first therapeutic aptamer was described nearly 25 years ago, and the subsequent first aptamer drug approved, many efforts have been made to translate preclinical research into clinical oncology settings. Studies of aptamer-based technology have unveiled the vast potential of aptamers in therapeutic and diagnostic applications. Among pediatric solid cancers, brain tumors are the leading cause of death. Although a few ap

APA, Harvard, Vancouver, ISO, and other styles

36

Shahriar, S., Jagannath Mondal, Mohammad Hasan, Vishnu Revuri, Dong Lee, and Yong-Kyu Lee. "Electrospinning Nanofibers for Therapeutics Delivery." Nanomaterials 9, no. 4 (2019): 532. http://dx.doi.org/10.3390/nano9040532.

Full text

Abstract:

The limitations of conventional therapeutic drugs necessitate the importance of developing novel therapeutics to treat diverse diseases. Conventional drugs have poor blood circulation time and are not stable or compatible with the biological system. Nanomaterials, with their exceptional structural properties, have gained significance as promising materials for the development of novel therapeutics. Nanofibers with unique physiochemical and biological properties have gained significant attention in the field of health care and biomedical research. The choice of a wide variety of materials for n

APA, Harvard, Vancouver, ISO, and other styles

37

Galdino da Rocha Pitta, Maira, Marina Galdino da Rocha Pitta, and Suely Lins Galdino. "Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides." Current Protein & Peptide Science 11, no. 3 (2010): 236–47. http://dx.doi.org/10.2174/138920310791112066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Palesh S Rajkondawar and Amit B Patil. "Nano-sponges: A Novel Carrier for Delivery of Chemo-therapeutic Drugs." International Journal of Research in Pharmaceutical Sciences 11, no. 1 (2020): 1040–44. http://dx.doi.org/10.26452/ijrps.v11i1.1933.

Full text

Abstract:

Nano-sponges belong to the category of hyper-cross linked polymer which is based on the colloidal structure. Nano-sized carriers are developed recently and are being used to deliver poorly water soluble drug by modifying the pharmaco-kinetic parameter and provide enhanced prolonged release. As a new class of chemo-therapeutic agents is being developed, formulation is getting difficult to issues such as poor solubility, low loading capacity and less entrapment of the drug in the drug delivery system. Nano-sponges have shown to deliver the most complex and challenging Chemo therapeutic drugs due

APA, Harvard, Vancouver, ISO, and other styles

39

Reiter, Karl, Valeria Bordoni, Giuliano Dall’Olio, et al. "In vitro Removal of Therapeutic Drugs with a Novel Adsorbent System." Blood Purification 20, no. 4 (2002): 380–88. http://dx.doi.org/10.1159/000063108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Cawston, Erin E., and Laurence J. Miller. "Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor." British Journal of Pharmacology 159, no. 5 (2009): 1009–21. http://dx.doi.org/10.1111/j.1476-5381.2009.00489.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ayla, Sule, Ayhan Bilir, Burak C. Soner, Ozlem Yilmaz-Dilsiz, Mine Ergüven, and Gulperi Oktem. "Notch Signaling–related Therapeutic Strategies With Novel Drugs in Neuroblastoma Spheroids." Journal of Pediatric Hematology/Oncology 36, no. 1 (2014): 37–44. http://dx.doi.org/10.1097/mph.0b013e3182755c73.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Steurer, M. "ASH 2010: new drugs and novel therapeutic concepts on the move." memo - Magazine of European Medical Oncology 4, no. 2 (2011): 62–63. http://dx.doi.org/10.1007/s12254-011-0270-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Mehanna, Ahmed S. "Novel Therapeutic Targets for Antiarrhythmic Drugs. Edited by George E. Billman." ChemMedChem 5, no. 7 (2010): 1152–53. http://dx.doi.org/10.1002/cmdc.201000151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Li, Fuquan, and Akhilesh Vikram Singh. "Recent advancements to enhance the therapeutic efficacy of antiepileptic drugs." Acta Pharmaceutica 71, no. 4 (2021): 527–44. http://dx.doi.org/10.2478/acph-2021-0041.

Full text

Abstract:

Abstract Epilepsy is a multifactorial neurological disorder characterized by recurrent or unprovoked seizures. Over the past two decades, many new antiepileptic drugs (AEDs) were developed and are in use for the treatment of epilepsy. However, drug resistance, drug-drug interaction and adverse events are common problems associated with AEDs. Antiepileptic drugs must be used only if the ratio of efficacy, safety, and tolerability of treatment are favorable and outweigh the disadvantages including treatment costs. The application of novel drug delivery techniques could enhance the efficacy and r

APA, Harvard, Vancouver, ISO, and other styles

45

Schaefer, Katherine L. "PPARγInhibitors as Novel Tubulin-Targeting Agents". PPAR Research 2008 (2008): 1–9. http://dx.doi.org/10.1155/2008/785405.

Full text

Abstract:

The microtubule-targeting agents (MTAs) are a very successful class of cancer drugs with therapeutic benefits in both hematopoietic and solid tumors. However, resistance to these drugs is a significant problem. Current MTAs bind to microtubules, and/or to their constituent tubulin heterodimers, and affect microtubule polymerization and dynamics. The PPARγinhibitor T0070907 can reduce tubulin levels in colorectal cancer cell lines and suppress tumor growth in a murine xenograft model. T0070907 does not alter microtubule polymerization in vitro, and does not appear to work by triggering modulati

APA, Harvard, Vancouver, ISO, and other styles

46

Lambert, W. Clark, and Monique M. Brown. "A Potential Novel Therapeutic Approach for Fanconi Anemia." Blood 112, no. 11 (2008): 1040. http://dx.doi.org/10.1182/blood.v112.11.1040.1040.

Full text

Abstract:

Abstract Lymphoblastoid cells from normal subjects and from patients with the bone marrow failure and cancer prone inherited disease, Fanconi anemia (FA) were treated in culture with psoralen plus ultraviolet A radiation (PUVA) in a scheme shown to produce interstrand crosslinks in cellular DNA. Hypersensitivity to DNA interstrand crosslinks, with associated increased clastogenicity, is considered to be a diagnostic hallmark of the disease. Following this cells were treated with hydroxyurea, 5 fluorouracil, or high dose thymidine for 24 hours. Clastogenicity and cytotoxicity, measured as trypa

APA, Harvard, Vancouver, ISO, and other styles

47

Rossi, Giuseppe, and Antonella Anastasia. "NOVEL DRUGS IN FOLLICULAR LYMPHOMA." Mediterranean Journal of Hematology and Infectious Diseases 8 (November 1, 2016): 2016061. http://dx.doi.org/10.4084/mjhid.2016.061.

Full text

Abstract:

Follicular lymphoma(FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% of lymphoma diagnoses. The natural history of the disease is characterized by recurrent relapses and progressively shorter remissions with a median survival of 10yrs. The impossibility of a chieving a definite cure, have prompted investigations into the possible role of more effective and less toxic strategies with innovative therapeutic agents. Recently Casulo et al demonstrated that approximately 20% of patients with FL actually relapse within 2 years after achieving remission with R-CHOP and

APA, Harvard, Vancouver, ISO, and other styles

48

Ananthy, Vimala, Raman P. Priyadharsini, and Umamaheswari Subramanian. "Drugs modulating apoptosis: current status." International Journal of Basic & Clinical Pharmacology 10, no. 7 (2021): 870. http://dx.doi.org/10.18203/2319-2003.ijbcp20212388.

Full text

Abstract:

Apoptosis (programmed cell death) is a natural process that helps in removing potentially harmful cells from the body and replacing it with normal ones. Like any other process, it is also subjected to lots of deregulations and can lead to diseases like cancer, neurodegenerative conditions, multiple sclerosis, Parkinson’s disease, autoimmune disorders and inappropriate death of cells after liver failure, stroke and myocardial infarction. The knowledge of the molecular mechanisms involved in apoptosis has been progressed tremendously. Thus, therapeutics targeting apoptosis have been emerged as a

APA, Harvard, Vancouver, ISO, and other styles

49

Fan, Shiyong, Dian Xiao, Yanming Wang, Lianqi Liu, Xinbo Zhou, and Wu Zhong. "Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2." Future Medicinal Chemistry 12, no. 17 (2020): 1565–78. http://dx.doi.org/10.4155/fmc-2020-0158.

Full text

Abstract:

SARS-CoV-2 has been widely spread around the world and COVID-19 was declared a global pandemic by the WHO. Limited clinically effective antiviral drugs are available now. The development of anti-SARS-CoV-2 drugs has become an urgent work worldwide. At present, potential therapeutic targets and drugs for SARS-CoV-2 are continuously reported, and many repositioning drugs are undergoing extensive clinical research, including remdesivir and chloroquine. On the other hand, structures of many important viral target proteins and host target proteins, including that of RdRp and Mpro were constantly re

APA, Harvard, Vancouver, ISO, and other styles

50

Bourdon, Allen K., Greg Villareal, George Perry, and Clyde F. Phelix. "Alzheimer's and Parkinson's Disease Novel Therapeutic Target." International Journal of Knowledge Discovery in Bioinformatics 7, no. 2 (2017): 68–82. http://dx.doi.org/10.4018/ijkdb.2017070104.

Full text

Abstract:

Thiazolidinedione (TZD) drugs (Takeda Pharmaceuticals and Metabolic Solutions Development Company) targeting inhibition of the mitochondrial pyruvate carrier (MPC) are currently being tested in clinical trials to prevent progression into mild cognitive impairment of Alzheimer's disease (AD) or in the pipeline to prevent neurodegeneration in Parkinson's disease (PD). These have Ki values in the µM range. This study was focused on identifying candidate drug precursors of the natural cinnamic acid products that might have good bioavailability in the nM ranges forming covalent thiol bonds with tar

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!